Search Results
Filgrastim-sndz
Filgrastim-sndz is FDA approved as a biosimilar to US-licensed Neupogen® for the five indications for which Neupogen is approved:
- Patients with cancer receiving myelosuppressive chemotherapy;
- Patients with acute myeloid leukemia receiving induction or consolidation chemotherapy;
- Patients with cancer undergoing bone marrow transplantation;
- Patients undergoing autologous peripheral blood progenitor cell collection and therapy; and
- Patients with severe chronic neutropenia.
Interferon alfa-2b
Interferons are substances naturally produced by cells in the body to help fight infections and tumors. They may also be synthetic versions of these substances.
Interferon alfa-2b is FDA approved to treat people who have hairy cell leukemia, polycythemia vera and aggressive follicular non-Hodgkin lymphoma.
Obinutuzumab
Obinutuzumab is FDA-approved
Pirtobrutinib
Pirtobrutinib is indicated for the treatment of
Gemtuzumab ozogamicin
Gemtuzumab ozogamicin is approved for the treatment of
- Newly-diagnosed CD33-positive acute myeloid leukemia (AML) in adults and pediatric patients 1 month and older
- Relapsed or refractory CD33-positive AML in adults and pediatric patients 2 years and older (1.2).
Enasidenib
Enasidenib (Idhifa®) is FDA approved for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation. The drug is approved for use with a companion diagnostic, the RealTime IDH2 Assay, which is used to detect specific mutations in the IDH2 gene in patients with AML.
“People Just Didn’t Get It”: Treating Young Adults with Cancer
Think of spring break: warm sunny skies, a refreshing drink, and hopefully, a feeling of freedom.
Daunorubicin and cytarabine
Daunorubicin and cytarabine is a liposomal combination of daunorubicin, an anthracycline topoisomerase inhibitor, and cytarabine, a nucleoside metabolic inhibitor, that is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
My Journey Through Stage IV Non-Hodgkin Lymphoma
Brittany Daniel is an actress best known for her role in the television series “Sweet Valley High” and the film, “Joe Dirt,” and a lifestyle blogger at The Sweet Life By Brittany + Cynthia Daniel. She and her husband, Adam, will participate in The Leukemia Cup Regatta in San Francisco (www.sflcr.org) on October 22.
A phase 1/2 study of DR-01, an anti-CD94 monoclonal antibody, in patients with large granular lymphocytic leukemia or cytotoxic lymphomas
In November 2022, LLS made an equity investment in Dren Bio to "Support Clinical Development of the DR-01 Program for Rare Leukemia & Lymphoma Indications Including Large Granular Lymphocyte Leukemia (LGLL) and Cytotoxic Lymphomas."Clofarabine
Clofarabine is FDA approved to treat children and young adults (1- 21 years old) with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.
Zanubrutinib
Zanubrutinib is indicated for the treatment of adult patients with:
Surviving Chemo: A Little Planning Goes a Long Way
Just the thought of chemotherapy can be enough to make one feel sick. Toxic drugs powerful enough to kill or damage cancer cells also take their toll on healthy cells. While everyone tends to respond differently, most agree the treatments come with unpleasant side effects.
Check out these 14 tips from The Leukemia & Lymphoma Society that should help make the experience a little less uncomfortable:
Fludarabine
Fludarabine is FDA approved to treat people who have chronic lymphocytic leukemia (CLL) who have not responded to at least one standard alkylting-agent-containing regimen or whose disease has progressed during treatment with such a regimen. This medicine may rarely cause a temporary loss of hair. After treatment with fludarabine has ended, normal hair growth should return.